Lymphoma

SOUTH SAN FRANCISCO-The FDA has approved a supplemental biological license application (sBLA) for Rituxan (rituximab), the monoclonal antibody developed by Genentech, Inc. and IDEC Pharmaceuticals (San Diego) for treatment of patient with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL). The new product labeling includes re-treatment with rituximab after a prior course, initial treatment with eight weekly infusions instead of four, and treatment of bulky disease.

WASHINGTON-A new evaluation of existing scientific studies has found "limited or suggestive" evidence to link servicemen’s wartime exposures to herbicides in Vietnam with the development of acute myelogenous leukemia (AML) in their children. However, the Institute of Medicine (IOM) committee that reported the finding emphasized that the evidence for the association is not conclusive.

WASHINGTON -The Food and Drug Administration, acting with dispatch, has approved the marketing of Gleevec (imatinib mesylate, Novartis) for the treatment of chronic myeloid leukemia (CML). The agency granted the drug priority review and orphan drug status, and approved it under the FDA’s "accelerated approval" regulations less than 3 months after the sponsor submitted its marketing request.

The exact mechanism of development of autoimmune hemolytic anemia (AIHA) in chronic lymphocytic leukemia (CLL) is unclear, but the imbalance among lymphocyte subsets is considered to be the basis for the emergence of an autoimmune

Treatment options for patients with relapsed chronic lymphocytic leukemia (CLL) are limited. In this report, we present our preliminary results of a biochemotherapy combination using rituximab (Rituxan, a monoclonal antibody against CD20) with

A total of 400 previously untreated elderly patients (aged 60 to 80) with stage II to IV diffuse large B-cell lymphoma (DLCL) were recruited to an open-label, randomized study of standard CHOP (cyclophosphamide [Cytoxan, Neosar],

Mantle cell lymphoma (MCL) has a low complete response (CR) rate (21%) after anthracycline-containing regimens, a short duration of response (median: 10 months), and dismal survival (median: 2 to 4 years). This improves to 100% after

We have previously reported that normal B lymphocytes in lymph nodes and peripheral blood of patients with Hodgkin’s disease (HD) express CD40 ligand (CD40L) and CD30 ligand (CD30L). Both ligands can activate NF-kb and promote

Stage IV indolent lymphomas are currently considered incurable disorders. However, the achievement of an early molecular remission, as determined by the bcl-2 polymerase chain reaction (PCR) assay, is associated with a better outcome. In view

Response rates up to 50% have been observed in patients with relapsed CD20-positive non-Hodgkin’s lymphoma after treatment with the chimeric monoclonal anti-CD20 antibody rituximab (Rituxan). The malignant cell population in

SAN FRANCISCO-An Italian study has found that Hodgkin’s disease is becoming more frequent than non-Hodgkin’s lymphoma (NHL) in people with HIV. The researchers speculate that this rise in Hodgkin’s disease may be due to the advent of highly active antiretro-viral therapy (HAART). Alessandro Re, MD, of the Universita di Brescia, presented the results at the American Society of Hematology annual meeting.

Patients with refractory/relapsed diffuse large B-cell non-Hodgkin’s lymphoma (NHL) who fail high-dose chemotherapy and stem cell transplant or are not suitable candidates for intensive therapy have limited therapeutic options. We have

Initial treatment of chronic lymphocytic leukemia (CLL) with fludarabine (Fludara) or fludarabine/cyclophosphamide (Cytoxan, Neosar) resulted in complete remission (CR) rates of 28% and 35%, respectively. Recently, rituximab (Rituxan)

Our objective was to determine the efficacy of a fludarabine (Fludara)/mitoxantrone (Novantrone) regimen combined with the monoclonal anti-CD20 antibody rituximab (Rituxan) to induce clinical and molecular remissions in patients with relapsed

We designed a phase II trial to determine the efficacy of the chimeric anti-CD20 monoclonal antibody rituximab (Rituxan) in lymphocyte-predominant Hodgkin’s disease (LPHD). A unique subtype of Hodgkin’s disease that expresses the CD20

Ibritumomab tiuxetan (Zevalin) is an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan, which forms a strong chelate with the pure beta-emitting isotope yttrium-90. We conducted an open-label trial of

HOUSTON-Chemoimmunotherapy with rituximab (Rituxan) plus fludarabine, novantrone (mitoxantrone), and dexamethasone (FND) reduced levels of a major tumor marker and significantly improved projected 2-year failure-free survival in patients with stage IV indolent follicular non-Hodgkin’s lymphomas (NHL) who had molecular responses after 6 months of treatment. Results from a randomized study of 134 previously untreated patients were presented by Fernando F. Cabanillas, MD, chairman of the Department of Lymphoma-Myeloma at the University of Texas M. D. Anderson Cancer Center in Houston.

STANFORD, California-Rituximab (Rituxan) is highly active in achieving clinical response in lymphoctye predominance Hodgkin’s disease (LPHD) and may ultimately have the potential of reducing long-term side effects and improving survival in this disease, according to the results of a phase-II trial. Although LPHD has effectively been treated with radiotherapy, chemotherapy, or a combined modality, a subset of patients experiences recurrence and treatment related morbidity and mortality-often from heart disease.

HOUSTON-Removing B cells improves control of classic Hodgkin’s disease and relieves B symptoms, reported Anas Younes, MD. Dr. Younes, associate professor, Department of Lymphoma/Myeloma at the University of Texas M. D. Anderson Cancer Center, Houston, Texas, administered the anti-CD20 monoclonal antibody rituximab (Rituxan) to heavily pretreated patients who had relapsed classic Hodgkin’s disease. The rationale behind this trial, according to Dr.Younes, was that B cells may provide survival and resistance signals to Reed-Sternberg (RS) cells in Hodgkin’s disease.

NEW YORK-The promise of molecularly targeted therapies has been validated in chronic myelogenous leukemia (CML), Brian J. Druker, MD, of Oregon Health Sciences University, Portland, said at the Chemotherapy Foundation Symposium XVIII. "This disease has provided an ideal opportunity to test the concept that drugs targeted against a tumor-specific abnormality will have therapeutic utility," he said.

SAN FRANCISCO-Patients receiving monoclonal antibody-targeted chemotherapy with gemtuzumab ozo-gamicin (Mylotarg) rather than conventional combination chemotherapy for first relapse of acute myelogenous leukemia (AML) are more likely to be treated as outpatients, resulting in considerable cost savings, according to a study from Fred Hutchinson Cancer Research Center and Wyeth-Ayerst Research.

SAN FRANCISCO-Results of a phase II, open-label, multicenter study show that the investigational agent STI571 holds promise for many patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) whose disease has proved resistant to interferon therapy.

SAN FRANCISCO-HIV-positive patients with Burkitt’s lymphoma treated with intensive chemotherapy achieved high complete response rates similar to those without HIV infection, according to a retrospective review of 38 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1988 and 2000.

Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to

Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to